ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements with these filters
Gujarat Themis Biosyn clarified its preferential issue of up to 82,10,786 shares at Rs 408. The filing covers utilisation timelines, allottee beneficial owners and a PCS certificate.
Gujarat Themis Biosyn scheduled its board meeting for 4 Nov 2026 to approve Q2 and H2 un-audited results. No financial figures are disclosed in this advance intimation.
Gujarat Themis Biosyn clarified that its 9 October 2026 credit-rating intimation was uploaded in error and should be disregarded. No substantive business event is reported.
Gujarat Themis Biosyn Limited submitted the mandatory quarterly compliance certificate under SEBI Regulation 74(5) regarding dematerialization of shares for the quarter ended September 30, 2026.
Gujarat Themis Biosyn Ltd held its 45th Annual General Meeting on September 30, 2026, to deliberate on ordinary and special business resolutions.
Gujarat Themis Biosyn issued a corrigendum to its 45th AGM notice, updating the preferential issue resolution regarding share price, issue size, and allottee details.
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
Gujarat Themis Biosyn Limited has fixed September 23, 2026, as the record date for determining member entitlement for the final dividend for FY 2025-26.
GTBL completed 100% acquisition of MBJ Japan for JPY 21.5 billion (~₹1,333 Cr). The deal adds three GMP plants and precision fermentation capabilities.
Gujarat Themis Biosyn Limited announced the allotment of non-convertible debt securities. The filing serves as a regulatory disclosure regarding the issuance of these instruments.
Gujarat Themis Biosyn Ltd has submitted its quarterly shareholding pattern. This filing is a routine disclosure mandated by SEBI regulations.
The board of Gujarat Themis Biosyn approved the issuance of Non-Convertible Debentures (NCDs) aggregating up to ₹585 Crore on a private placement basis.
Gujarat Themis Biosyn Ltd has scheduled a board meeting for September 10, 2026, to consider raising funds through the private placement of non-convertible debentures.
Gujarat Themis Biosyn Limited has filed its Integrated Annual Report for the FY 2025-26 in compliance with SEBI LODR regulations.
Gujarat Themis Biosyn Limited issued a notice for its 45th Annual General Meeting scheduled for September 30, 2026, to transact various ordinary and special business items.
Gujarat Themis Biosyn Limited approved a preferential issue of 82,10,786 shares at Rs. 408 each, aggregating to Rs. 335.00 Crore.
Gujarat Themis Biosyn Limited has successfully completed a Qualified Institutional Placement (QIP), allotting new equity shares. This capital raise increases the total paid-up share capital.
Gujarat Themis Biosyn closed its QIP, allocating 2,11,86,440 equity shares at ₹354 per share. This issuance raises ₹750.00 Crore for the company.
Gujarat Themis Biosyn Limited scheduled a Board Meeting for September 1, 2026. The board will consider raising funds via preferential issue of shares and warrants.
Gujarat Themis Biosyn's board approved the preliminary placement document and set a floor price of ₹372.57 per share for its upcoming Qualified Institutions Placement (QIP).
Gujarat Themis Biosyn Limited has amended its Articles of Association following shareholder approval via a Special Resolution at the Extraordinary General Meeting.
Gujarat Themis Biosyn Limited held its Extraordinary General Meeting on August 22, 2026, where shareholders approved special business resolutions including the private placement of debt securities.
GTBL reported strong Q1FY27 growth with 22.1% revenue and PAT increases, driven by sales volumes. Strategy is shifting toward becoming an integrated fermentation-led CDMO via major acquisitions and API forward integration.